419: Initial cyclosporin C2 monitoring following lung transplantation provides long-term clinical benefits: A prospective randomised study

Tacrolimus in 33 patients, group B; Pre-LT lymphocyte depletion with anti-CD3 Ab (Thymoglobulin), followed by Tacrolimus in 33 patients, group C; No induction, followed by post-LT triple-drug therapy (Tacrolimus/ Cyclosporine A Azathioprine steroids) in 49 patients, group D. The presence of preand post-transplant HLA-Ab was prospectively determined by ELISA, while the specificity of HLA-Ab by single-antigen ELISA and/or Luminex. Results: The prevalence of de novo HLA-Ab in the first year after LT was only 5% in patients who received MMF (group A), significantly lower than in the other groups (18-30%, table). There were no statistically differences between the groups without MMF regarding the prevalence of de novo HLA-Ab. Conclusions: In lung transplantation, the addition of MMF in the immunosuppressive regimen was associated with a lower humoral sensitization.